Status:
COMPLETED
An Oral p38 Inhibitor Investigating Safety, Efficacy, And PK In Subjects With Active Rheumatoid Arthritis
Lead Sponsor:
Pfizer
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
19-90 years
Phase:
PHASE2
Brief Summary
Investigating the safety and tolerability of a p38 inhibitor as monotherapy in subjects who have failed at least 1 DMARD.
Eligibility Criteria
Inclusion
- Diagnosed with RA and has failed at least 1 DMARD therapy
Exclusion
- Any other inflammatory arthritis and any significant history of acute or chronic infection with immunomodulatory etiology.
Key Trial Info
Start Date :
December 15 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 16 2008
Estimated Enrollment :
305 Patients enrolled
Trial Details
Trial ID
NCT00383188
Start Date
December 15 2006
End Date
July 16 2008
Last Update
August 20 2021
Active Locations (48)
Enter a location and click search to find clinical trials sorted by distance.
1
Emeritus Research
Malvern East, Victoria, Australia, 3145
2
Centro de Estudos em Terapias Inovadoras
Curitiba, Paraná, Brazil, 80060-240
3
Hospital de Clínicas da UFPR
Curitiba, Paraná, Brazil, 80060-900
4
Escola Paulista de Medicina - EPM
São Paulo, São Paulo, Brazil, 04026-000